Zola Ndandu, MD
Interventional Cardiology · East Palatka, FLNPI 1598955973
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (53.4%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 35 manufacturers reported payments, led by Bard Peripheral Vascular, Inc. at 31.8% of the total. 2025 is the largest year on record at $29,657, more than ten times the $2,000 reported in 2019. Among interventional cardiology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 281 payments — averaging $373.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bard Peripheral Vascular, Inc.$33K
- Boston Scientific$29K
- Abbott$18K
- W. L. Gore & Associates, Inc.$7K
- Terumo Medical Corporation$6K
- Lilly USA, LLC$2K
- plus $9K from 29 others
Across 21 payments — averaging $2227.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$31K
- Abbott$16K
What the payments were for
- Consulting fees$56,07353%
- Speaking & faculty fees$33,02531%
- Travel & lodging$3,0953%
- Food & beverage$12,85012%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bard Peripheral Vascular, Inc. | 46 | $33,433 |
| Boston Scientific | 49 | $28,669 |
| Abbott | 42 | $18,049 |
| W. L. Gore & Associates, Inc. | 18 | $7,457 |
| Terumo Medical Corporation | 11 | $5,792 |
| Lilly USA, LLC | 2 | $2,300 |
| Johnson & Johnson | 13 | $1,557 |
| Endologix LLC | 5 | $1,379 |
| Inari Medical, Inc. | 7 | $1,050 |
| Cordis US CORP. | 2 | $565 |
| Angiodynamics, Inc. | 13 | $496 |
| Philips North America LLC | 7 | $476 |
| Medtronic(2 entities) | 10 | $396 |
| Penumbra, Inc. | 4 | $389 |
| Shockwave Medical, Inc | 4 | $374 |
| Limflow Inc. | 1 | $317 |
| Integra Lifesciences Corporation | 2 | $300 |
| E.r. Squibb & Sons, L.L.C. | 12 | $295 |
| Abiomed | 2 | $278 |
| Stryker | 4 | $252 |
| Reflow Medical Inc | 1 | $224 |
| Edwards Lifesciences | 1 | $124 |
| Mercator Medsystems, Inc. | 1 | $124 |
| Asahi Intecc USA, Inc. | 2 | $118 |
| Cardiovascular Systems Inc. | 1 | $116 |
| Surmodics, Inc. | 2 | $112 |
| Merck | 5 | $88 |
| Novartis | 4 | $77 |
| Janssen Scientific Affairs, LLC | 3 | $68 |
| Amgen | 2 | $49 |
| Teleflex LLC | 1 | $36 |
| Nipro Medical Corporation | 1 | $27 |
| Vital Connect, Inc | 1 | $23 |
| Esperion Therapeutics, Inc. | 1 | $21 |
| Pfizer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - THERAPIES$16,220
- EKOSONIC$7,417
- SUPERA$6,413
- Product in Development$4,580
- Perclose ProGlide suture mediated closure system$2,750
- XIENCE SIERRA$2,500
- GORE VIABAHN VBX Balloon Expandable Endo$2,430
- JARDIANCE$2,300
- Optitorque$2,250
- GORE VIABAHN Endoprosthesis with Heparin$2,160
- ABSOLUTE PRO$2,000
- Ranger$1,875
- ESPRIT$1,809
- GENERAL VASCULAR INTERVENTION$1,577
- Supera peripheral stent system$1,364
- XARELTO$1,350
- GLIDESHEATH SLENDER$1,350
- Torus Stent Graft System$1,303
- ENDOCROSS Device$1,303
- FLOWTRIEVER CATHETER, S$1,171
How this compares
$105,043 in reported general payments places this provider in the 90th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 52 | $43,187 |
| XareltoRivaroxaban | 31 | $32,694 |
| EntrestoSacubitril/Valsartan | 20 | $23,949 |
| Repatha SureclickEvolocumab | 28 | $14,984 |
| Repatha SyringeEvolocumab | 17 | $9,457 |
| Rosuvastatin Calcium | 169 | $1,750 |
| Ranolazine ErRanolazine | 14 | $1,151 |
| Cilostazol | 39 | $1,067 |
| Metoprolol Succinate | 67 | $728 |
| ClopidogrelClopidogrel Bisulfate | 64 | $699 |
| Atorvastatin Calcium | 57 | $496 |
| Ezetimibe | 27 | $436 |
| Amiodarone Hcl | 20 | $300 |
| Losartan Potassium | 35 | $230 |
| Furosemide | 45 | $206 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $14 | $43,18752 claims |
| Johnson & JohnsonXarelto | $1,557 | $32,69431 claims |
| NovartisEntresto | $77 | $23,94920 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in East Palatka
- Imraan AnsaarieEast Palatka$165K
- Arthur LeeGainesville$1.8M
- Santhosh MathewsBradenton$1.4M
- Siddharth WayangankarJacksonville$1.2M
- Patrick CambierTrinity$901K
- Zahid AminOrlando$635K
- Rohit AminPensacola$560K
- Eduardo de MarchenaMiami$498K
- Dominick AngiolilloJacksonville$387K
- Miguel DiazHialeah$383K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.